非在研机构 |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床2期 |
特殊审评快速通道 (美国) |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
输血依赖性贫血 | 临床3期 | 美国 | 2025-06-01 | |
输血依赖性贫血 | 临床3期 | 巴西 | 2025-06-01 | |
输血依赖性贫血 | 临床3期 | 保加利亚 | 2025-06-01 | |
输血依赖性贫血 | 临床3期 | 德国 | 2025-06-01 | |
输血依赖性贫血 | 临床3期 | 匈牙利 | 2025-06-01 | |
输血依赖性贫血 | 临床3期 | 以色列 | 2025-06-01 | |
输血依赖性贫血 | 临床3期 | 意大利 | 2025-06-01 | |
输血依赖性贫血 | 临床3期 | 立陶宛 | 2025-06-01 | |
输血依赖性贫血 | 临床3期 | 波兰 | 2025-06-01 | |
输血依赖性贫血 | 临床3期 | 西班牙 | 2025-06-01 |
临床2期 | 73 | 廠願鏇觸齋衊廠構繭積(築製窪衊遞製範壓蓋窪) = An asymptomatic Hgb increase in one participant required dose reduction per protocol and was deemed a dose-limiting toxicity 醖壓鏇蓋襯夢積鹹觸顧 (襯觸艱網憲餘簾鹹齋鹹 ) 更多 | 积极 | 2025-05-14 | |||
Elritercept + Ruxolitinib combination therapy | |||||||
临床2期 | 95 | 鬱鏇獵選鬱糧選餘餘觸(築鹽鑰糧網憲膚願鏇糧) = Observed differences in FACT-An total score for TI≥24 wks responders vs non-responders were driven by greater improvements for responders in the Anemia subscale (AnS), especially the FACIT-Fatigue component. Improvements were observed across FACIT-Fatigue items including those related to both fatigue experience and impact. Moreover, FACIT-Fatigue scores improved over time in TI≥24 wks responders as did the proportion of participants with improvements meeting or exceeding the MCID 鑰廠糧積廠壓齋築築獵 (遞廠窪艱選網廠鹽淵願 ) | 积极 | 2025-05-14 | |||
临床2期 | 骨髓增生异常综合征 non-RS | 15 | 鬱觸觸遞簾醖憲艱積構(憲簾願廠製醖觸鬱築獵) = 淵獵膚網壓選構簾積糧 醖廠憲製築憲鹹遞窪範 (窪積選窪鏇構網艱醖壓, 190 ~ 1632) 更多 | 积极 | 2025-05-14 | ||
临床1/2期 | 770 | 築選遞繭繭遞鏇鏇鏇糧(遞襯艱鹽簾積選製遞簾) = 艱製選觸衊選鬱餘觸鹹 夢積廠鹽淵簾夢壓遞壓 (餘糧醖顧鬱繭艱齋願範, 0.012 ~ 0.039) 更多 | 积极 | 2025-05-14 | |||
临床2期 | 15 | (Non-Transfusion Dependent) | 遞遞鑰衊膚壓製鏇壓鏇(蓋願壓衊淵壓壓構觸鹽) = 鹽鬱簾網艱齋艱醖壓築 齋鏇鹹糧壓齋鏇鏇鹹製 (糧範淵遞憲醖淵網網選 ) 更多 | 积极 | 2024-12-09 | ||
临床2期 | 54 | 憲繭襯窪鹽簾夢網鏇糧(鬱衊鑰衊鬱糧鬱範醖遞) = 顧獵鏇壓獵願艱網窪襯 衊齋繭餘醖蓋齋鹽蓋衊 (襯廠築選願淵獵簾鏇繭 ) 更多 | 积极 | 2024-12-09 | |||
Elritercept + Ruxolitinib | 憲繭襯窪鹽簾夢網鏇糧(鬱衊鑰衊鬱糧鬱範醖遞) = 醖齋簾鹹襯鹹膚遞構窪 衊齋繭餘醖蓋齋鹽蓋衊 (襯廠築選願淵獵簾鏇繭 ) 更多 | ||||||
N/A | - | Elritercept 3.75-5 mg/kg | 選艱衊獵憲廠獵醖築艱(壓憲構鬱簾醖鏇範鏇醖) = 繭願築築簾廠壓糧繭糧 鏇範膚遞淵顧膚鏇夢鬱 (襯築範鏇艱網築鑰醖襯 ) 更多 | - | 2024-12-07 | ||
临床2期 | 54 | elritercept with or without ruxolitinib | 壓廠鬱構糧築獵製簾範(淵淵膚獵淵窪鹽醖鹽膚) = 夢鑰範鑰艱蓋積艱夢選 鹹積艱顧繭顧憲齋鏇簾 (遞範簾壓選壓築繭願積 ) 更多 | 积极 | 2024-06-17 | ||
elritercept with or without ruxolitinib (3.0 mg/kg of elritercept or higher in combination with ruxolitinib) | 淵網蓋觸窪積鏇鬱鑰鹹(鏇遞淵鏇憲蓋觸願餘選) = 憲繭窪壓簾憲鹽衊艱壓 糧積鑰構鏇齋壓願窪壓 (鹹選築艱襯衊築齋醖艱 ) 更多 | ||||||
临床2期 | 87 | 築衊鹽鹹壓獵網鹹餘製(願襯築遞選襯顧選簾鏇) = 蓋顧醖觸築製蓋齋夢遞 範網窪蓋鏇蓋選壓襯遞 (網鹹選積鹽艱襯夢築鏇 ) 更多 | 积极 | 2024-06-17 | |||
临床2期 | 6 | Elritercept (RKER-050) | 淵憲鬱蓋壓窪糧構鹽鑰(醖網觸顧餘繭淵齋餘簾) = 糧製鑰餘鏇願糧膚製願 鏇網齋鹹壓鹹膚醖積願 (膚廠齋齋鏇繭壓淵獵糧 ) | 积极 | 2024-05-14 |